These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27158552)

  • 41. Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine.
    Quinet B; Laudat F; Gurtman A; Patterson S; Sidhu M; Gruber WC; Scott DA
    Pediatr Infect Dis J; 2014 Oct; 33(10):1065-76. PubMed ID: 25093973
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses.
    Kawakami K; Kishino H; Kanazu S; Toshimizu N; Takahashi K; Sterling T; Wang M; Musey L
    Vaccine; 2016 Jul; 34(33):3875-81. PubMed ID: 27265450
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease.
    Vernacchio L; Romero-Steiner S; Martinez JE; MacDonald K; Barnard S; Pilishvili T; Carlone GM; Ambrosino DM; Molrine DC
    J Infect Dis; 2000 Mar; 181(3):1162-6. PubMed ID: 10720547
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial.
    Ahmed F; Steinhoff MC; Rodriguez-Barradas MC; Hamilton RG; Musher DM; Nelson KE
    J Infect Dis; 1996 Jan; 173(1):83-90. PubMed ID: 8537687
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunoglobulins and immunogenicity of pneumococcal vaccination in preschool asthma.
    Rose MA; Schubert R; Kujumdshiev S; Kitz R; Zielen S
    Int J Clin Pract; 2006 Nov; 60(11):1425-31. PubMed ID: 17073839
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults.
    Schmoele-Thoma B; van Cleeff M; Greenberg RN; Gurtman A; Jones TR; Sundaraiyer V; Gruber WC; Scott DA
    Hum Vaccin Immunother; 2019; 15(3):575-583. PubMed ID: 30648932
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy.
    Trück J; Jawad S; Goldblatt D; Roalfe L; Snape MD; Voysey M; Pollard AJ
    Pediatr Infect Dis J; 2016 Jul; 35(7):787-93. PubMed ID: 27088583
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenicity of a 7-valent pneumococcal conjugate vaccine (PCV7) and impact on carriage in Venezuelan children at risk of invasive pneumococcal diseases.
    Rivera-Olivero IA; Del Nogal B; Fuentes M; Cortez R; Bogaert D; Hermans PW; Waard JH
    Vaccine; 2014 Jun; 32(31):4006-11. PubMed ID: 24837505
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity differences of a 15-valent pneumococcal polysaccharide conjugate vaccine (PCV15) based on vaccine dose, route of immunization and mouse strain.
    Caro-Aguilar I; Indrawati L; Kaufhold RM; Gaunt C; Zhang Y; Nawrocki DK; Giovarelli C; Winters MA; Smith WJ; Heinrichs J; Skinner JM
    Vaccine; 2017 Feb; 35(6):865-872. PubMed ID: 28087148
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: translating research into policy.
    Madhi SA; Cohen C; von Gottberg A
    Vaccine; 2012 Sep; 30 Suppl 3():C21-7. PubMed ID: 22939016
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study.
    Dicko A; Dicko Y; Barry A; Sidibe Y; Mahamar A; Santara G; Dolo A; Diallo A; Doumbo O; Shafi F; François N; Yarzabal JP; Strezova A; Borys D; Schuerman L
    Hum Vaccin Immunother; 2015; 11(9):2207-14. PubMed ID: 26020101
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment of antibody response elicited by a 7-valent pneumococcal conjugate vaccine in pediatric human immunodeficiency virus infection.
    Tarragó D; Casal J; Ruiz-Contreras J; Ramos JT; Rojo P; Snippe H; Jansen WT;
    Clin Diagn Lab Immunol; 2005 Jan; 12(1):165-70. PubMed ID: 15643002
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age.
    Ermlich SJ; Andrews CP; Folkerth S; Rupp R; Greenberg D; McFetridge RD; Hartzel J; Marchese RD; Stek JE; Abeygunawardana C; Musey LK
    Vaccine; 2018 Oct; 36(45):6875-6882. PubMed ID: 29559167
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Functional immune responses to 11 non-PCV13 serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults.
    Lee S; Kim HW; Lee JH; Kim KH
    Vaccine; 2017 Sep; 35(37):4960-4965. PubMed ID: 28778614
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Conjugate and 23-valent pneumococcal polysaccharide booster vaccination in asplenic patients with thalassemia major: A randomized clinical trial study.
    Rezai MS; Ghaffari J; Mahdavi M; Bahari A; Ala S
    Caspian J Intern Med; 2017; 8(1):16-22. PubMed ID: 28503278
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia.
    Urbancikova I; Prymula R; Goldblatt D; Roalfe L; Prymulova K; Kosina P
    Vaccine; 2017 Sep; 35(38):5186-5193. PubMed ID: 28797727
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adults.
    Rabian C; Tschöpe I; Lesprit P; Katlama C; Molina JM; Meynard JL; Delfraissy JF; Chêne G; Lévy Y;
    Clin Infect Dis; 2010 Apr; 50(8):1174-83. PubMed ID: 20210645
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults.
    Belmonti S; Rossetti B; Modica S; Paglicci L; Borghetti A; Ciccullo A; Picarelli C; Cauda R; De Luca A; Montagnani F; Lombardi F
    Infect Dis Ther; 2019 Sep; 8(3):453-462. PubMed ID: 31364010
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.
    de Roux A; Schmöle-Thoma B; Siber GR; Hackell JG; Kuhnke A; Ahlers N; Baker SA; Razmpour A; Emini EA; Fernsten PD; Gruber WC; Lockhart S; Burkhardt O; Welte T; Lode HM
    Clin Infect Dis; 2008 Apr; 46(7):1015-23. PubMed ID: 18444818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.